TransMedics (NASDAQ:TMDX) has emerged as a prominent player in the medical field, witnessing a remarkable surge from $14 to $90 in a little over 18 months.
The company’s core expertise lies in organ care systems, which preserve transplant organs post-donor retrieval.
Have you ever been to a public restroom and wondered how the company that runs the soap dispensary fares? If not, let me lift the veil. If so, you may already be familiar with the name Cintas.
Cintas Corporation (NASDAQ:CTAS) is a leading provider of restroom supplies,
» Read more about: Spotlight: 1 Stunning Stock To Hold For 10 Years »
Rates are going up everywhere, at least that’s what the financial press would have you believe. On July 26, Federal Reserve Chairman Jerome Powell oversaw a rate hike that placed interest rates at 22 year highs, pegging them at 5.25-5.50%.
The market had largely priced in the rate hike and so the S&P 500 fell just 0.17% on the day.
» Read more about: Spotlight: Dine On Steak After This Brazilian Breakout »
The turtle and hare game is so apt in investing. Why chase the fast bucks when slow and steady wins the race? Where investing gets tough is when the tortoise approach turns into a game of switcharoo, where you the investor gets the rug pulled on you. What am I talking about?
» Read more about: Spotlight: Are You About To Lose A Fortune? »
Perhaps there is no better technical pattern to master if you want to consistently and predictably generate superior returns than the breakout.
It’s a generic term that applies to a wide range of chart patterns, including basic support and resistance, as well as flag patterns, cup-and-handles, and many others. So,
Cannabis company SNDL, formerly known as Sundial Growers, has fallen more than 99 percent from its record closing high of $130. Now trading at less than $1.50 per share, the stock has been one of the biggest losers of the last few years. Its massive contraction in value, however, has left many investors wondering whether it has become oversold.
» Read more about: Spotlight: 99% Lower, Time To Buy This Weed Stock? »
Canopy Growth was at the forefront of the cannabis industry just a few years ago. But the Canadian cannabis producer has faced significant struggles that have reduced its valuation from billions to millions, as revenues have declined and losses have piled up.
In 2018, Canopy stock pushed past $50 per share, but investors have gradually given up on the stock since then.
» Read more about: Spotlight: Will This Weed Stock Get Your Portfolio High? »
CAVA debuted on the New York Stock Exchange on June 16, selling 14.4 million shares and raising a cash hoard of $318 million at a valuation just under $2.5 billion.
Eagle-eyed investors were stunned to see the share price soar by as much as 117%, before ultimately closing at $43.78 per share, slightly above its $42 open.
» Read more about: Spotlight: Should Sweetgreen Be 50% Higher? »
“Tesla is just a car company. It trades at a premium to other car manufacturers. The valuation is crazy” – that was the refrain from Tesla bears for years. And without doing a deep dive into Tesla, it seemed reasonable. After all, a car is a car. Analyze the number of units sold…
